Fintel reports that on April 10, 2026, Needham initiated coverage of Lyell Immunopharma (NasdaqGS:LYEL) with a Buy recommendation.
Analyst Price Forecast Suggests 79.19% Upside
As of April 9, 2026, the average one-year price target for Lyell Immunopharma is $40.12/share. The forecasts range from a low of $34.34 to a high of $47.25. The average price target represents an increase of 79.19% from its latest reported closing price of $22.39 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Lyell Immunopharma is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -0.88.
What is the Fund Sentiment?
There are 72 funds or institutions reporting positions in Lyell Immunopharma. This is an decrease of 31 owner(s) or 30.10% in the last quarter. Average portfolio weight of all funds dedicated to LYEL is 1.73%, an increase of 225.61%. Total shares owned by institutions increased in the last three months by 24.15% to 12,253K shares. 
The put/call ratio of LYEL is 0.15, indicating a bullish outlook.
What are Other Shareholders Doing?
Arch Venture holds 2,759K shares representing 11.83% ownership of the company. No change in the last quarter.
Glaxosmithkline holds 1,513K shares representing 6.48% ownership of the company.
MWG Caph holds 1,008K shares representing 4.32% ownership of the company.
MWG Management holds 1,008K shares representing 4.32% ownership of the company.
Foresite Capital Management Iv holds 800K shares representing 3.43% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
